5-ethyl-3-methyl-1,3-oxazolidin-2-one | 95911-34-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-ethyl-3-methyl-1,3-oxazolidin-2-one
• CAS: 95911-34-5
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: OEJGYJOUKPGWEB-UHFFFAOYSA-N

物化性质

• 沸点：
  264.3±9.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-methyl-1-amino-2-butanol 、 苯 以80%的产率得到
  参考文献：
  名称：

  MATSUDA, HARUO;BABA, AKIO;NOMURA, RYOKI;KORI, MASAKUNI;OGAWA, SACHIKO, IND. AND ENG. CHEM. PROD. RES. AND DEV., 1985, 24, N 2, 239-242

  摘要：

  DOI：

文献信息

• OXAZOLIDINONE ANTIBIOTIC DERIVATIVES
  申请人：Gude Markus

  公开号：US20100137290A1

  公开（公告）日：2010-06-03

  The invention relates to antibacterial compounds of formula I wherein R 1 is hydrogen, halogen, hydroxy, alkoxy or cyano; Y 1 and Y 2 each represent CH, one or two of U, V, W and X represent(s) N and the remaining each represent CH or, in the case of X, may also represent CR a , R a being halogen, and, in the case of W, may also represent CR b , or each of U, V, W, X, Y 1 and Y 2 represents CH, or each of U, V, W, X and Y 1 represents CH and Y 2 represents N, or also one or, provided R 1 is hydrogen, two of U, V, W, X, Y 1 and Y 2 represent(s) CRC and the remaining each represent CH, R b being alkoxy, alkoxycarbonyl or alkoxyalkoxy and R c being, each time it occurs, independently represents hydroxy or alkoxy; A-B-D represents a chain of 4 to 6 atoms, which 4 to 6 atoms are seleted from carbon, oxygen and nitrogen and may be substituted; E is one of the following groups: in which Z is CH or N and Q is O or S, or E is a phenyl group which is substituted once or twice in the meta and/or para position(s); and to salts of such compounds.

  本发明涉及式I的抗菌化合物，其中R1为氢、卤素、羟基、烷氧基或氰基；Y1和Y2各自代表CH，一个或两个U、V、W和X代表N，其余各自代表CH，或者在X的情况下，也可以代表CRa，其中Ra为卤素，并且在W的情况下，也可以代表CRb，或者U、V、W、X、Y1和Y2各自代表CH，或者U、V、W、X和Y1各自代表CH，而Y2代表N，或者，如果R1为氢，则一个或两个U、V、W、X、Y1和Y2代表CRC，其余各自代表CH，其中Rb为烷氧基、烷氧羰基或烷氧基烷氧基，Rc每次出现时独立地代表羟基或烷氧基；A-B-D代表4至6个原子的链，这4至6个原子选自碳、氧和氮，并且可以被取代；E是以下组之一：其中Z为CH或N，Q为O或S，或者E为苯基，该苯基在间位和/或对位被取代一次或两次；以及这类化合物的盐。
• Selective Formation of α-Cleavage Cycloadduct of Oxirane with Heterocumulene Promoted by High-Coordinated Trialkyltin Complexes
  作者：Katsunori Yano、Nobuyoshi Amishiro、Akio Baba、Haruo Matsuda

  DOI：10.1246/bcsj.64.2661

  日期：1991.9

  In the reaction of monosubstituted oxiranes and heterocumulenes, trialkyltin iodides coordinated by phosphine oxides effectively catalyzed the formation of heterocycles via cleavage at the substituted site in the oxirane ring, while other types of organotin complexes or noncomplexed organotin iodides promoted selective cleavage at the opposite site. A mechanistic investigation demonstrated that the

  在单取代环氧乙烷和杂枯草烯的反应中，氧化膦配位的三烷基锡碘化物通过环氧乙烷环中取代位点的裂解有效催化杂环的形成，而其他类型的有机锡络合物或未络合的有机锡碘化物则促进了相反位点的选择性裂解。机理研究表明，氧化膦的配位促进了环氧乙烷环裂解的逆反应，导致主要形成 α-裂解环加合物。
• CYCLIZED DERIVATIVES AS EG-5 INHIBITORS
  申请人：Boyce Rustum

  公开号：US20120189623A1

  公开（公告）日：2012-07-26

  The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:

  本发明涉及具有以下式（I）的新取代咪唑化合物及其药学上可接受的盐、酯或前药，以及该化合物与药学上可接受的载体的组合物和该化合物的用途：
• NMDA Receptor Antagonists for Neuroprotection
  申请人：Liotta Dennis C.

  公开号：US20140031363A1

  公开（公告）日：2014-01-30

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L) k -Ar 1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR 1 or O and each R 1 and R 2 is independently H, alkyl, alkenyl or aralkyl or R 1 and R 2 taken together form a 5-8 membered ring; R 3 -R 6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO 2 , CH 2 , NH, N(alkyl), or NHC(═O); and Z is OH, NR 6 R 7 , NR 8 SO 2 (alkyl), NR 8 C(O)NR 6 R 7 , NR 8 C(O)O(alkyl), NR 8 -dihydrothiazole, or NR 8 -dihydroimidazole or wherein Z can fuse with Ar 2 to form selected heterocycles.

  本发明提供了与NMDA受体活性相关的疾病的化合物、药物组合物和治疗或预防方法，包括神经病性疼痛、中风、创伤性脑损伤、癫痫和相关的神经事件或神经退行性疾病。提供了一般式I的化合物或其药学上可接受的盐、酯、前药或衍生物：其中：每个（L）k-Ar1是取代或未取代的、单环或双环芳基或杂环芳基；W是键、烷基或烯基；X是键、NR1或O，每个R1和R2独立地是H、烷基、烯基或芳基烷基，或者R1和R2共同形成一个5-8成员环；R3-R6选择自某些特定的取代基或羰基；Y是键、O、S、SO、SO2、CH2、NH、N（烷基）或NHC（═O）；Z是OH、NR6R7、NR8SO2（烷基）、NR8C（O）NR6R7、NR8C（O）O（烷基）、NR8-二氢噻唑或NR8-二氢咪唑，或者Z可以与Ar2融合形成选择的杂环。
• Cyclized Derivatives as EG-5 Inhibitors
  申请人：Boyce Rustum

  公开号：US20110003791A1

  公开（公告）日：2011-01-06

  The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:

  本发明涉及新的取代咪唑化合物，具有以下式子（I），以及其药学上可接受的盐、酯或前药，与药学上可接受的载体的化合物组合物，以及化合物的用途：